Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Endocrinol., 15 April 2025

Sec. Adrenal Endocrinology

Volume 16 - 2025 | https://doi.org/10.3389/fendo.2025.1593408

This article is part of the Research TopicEnhancing Adrenal Tumor Diagnostics: Biomarkers and Molecular MechanismsView all 12 articles

Corrigendum: The value of targeted CXCR4 18F-AlF-NOTA-pentixafor PET/CT for subtyping primary aldosteronism

This article is a correction to:

  1. The Value of Targeted CXCR4 18 F-AlF-NOTA-Pentixafor PET/CT for Subtyping Primary Aldosteronism

    1. Read original article
Yushi PengYushi Peng1Fangansheng ChenFangansheng Chen1Rui YaoRui Yao1Junping LanJunping Lan2Yinuo FuYinuo Fu3Kaifeng YeKaifeng Ye3Zhiqiang WangZhiqiang Wang1Qianxiu ZhaoQianxiu Zhao4Xiaowei JiXiaowei Ji1Kang XiaKang Xia4Guoqing ZhuGuoqing Zhu5Kewen ZhengKewen Zheng6Xuemei Gu*&#x;Xuemei Gu4*†Kun Tang,,*&#x;Kun Tang1,7,8*†
  • 1Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 2Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 3The First School of Clinical Medicine, Wenzhou Medical University, Wenzhou, China
  • 4Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 5Department of Interventional Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 6Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
  • 7Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province, Wenzhou, China
  • 8Key Laboratory of Novel Nuclide Technologies on Precision Diagnosis and Treatment & Clinical Transformation of Wenzhou City, Wenzhou, China

A Corrigendum on
The value of targeted CXCR4 18F-AlF-NOTA-pentixafor PET/CT for subtyping primary aldosteronism

by Peng Y, Chen F, Yao R, Lan J, Fu Y, Ye K, Wang Z, Zhao Q, Ji X, Xia K, Zhu G, Zheng K, Gu X and Tang K (2025) Front. Endocrinol. 16:1533295. doi: 10.3389/fendo.2025.1533295

In the published article, there was an error in Figure 7 as published. We mistakenly exported and uploaded this figure. The corrected Figure 7 and its caption appear below.

Figure 7
www.frontiersin.org

Figure 7. The receiver operating characteristic curve of SUVmax, LAR, LLR and visual analysis for identifying surgically eligible lesions and surgically ineligible lesions.

In the published article, there was an error in section 2. Materials and Methods, Adrenal Venous Sampling Interpretation, Paragraph 1. The following sentence was removed.

“If the ratio of aldosterone/cortisol in the high-side adrenal vein blood to the low-side adrenal vein blood is 4 or greater, it indicates increased aldosterone secretion from one side of the adrenal gland, which is diagnosed as APA.”

In the published article, there was an error in section 3. Results, Diagnostic Accuracy of 18F-AlF-NOTA-pentixafor PET/CT for surgically eligible lesions, Paragraph 1. The following sentence was removed.

“Among enrolled patients, 2 UPA patients exhibited 2 hot nodules in the ipsilateral adrenal gland, 2 UPA patients exhibited a cold lesion contralateral to the UPA lesion, and 3 NFA patients exhibited bilateral nodules. The remaining 81 patients displayed unilateral adrenal gland lesions on CT scans.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: primary aldosteronism, CXCR4, 18 F-pentixafor, PET/CT, subtyping, treatment

Citation: Peng Y, Chen F, Yao R, Lan J, Fu Y, Ye K, Wang Z, Zhao Q, Ji X, Xia K, Zhu G, Zheng K, Gu X and Tang K (2025) Corrigendum: The value of targeted CXCR4 18F-AlF-NOTA-pentixafor PET/CT for subtyping primary aldosteronism. Front. Endocrinol. 16:1593408. doi: 10.3389/fendo.2025.1593408

Received: 14 March 2025; Accepted: 26 March 2025;
Published: 15 April 2025.

Edited and Reviewed by:

Henrik Falhammar, Karolinska Institutet (KI), Sweden

Copyright © 2025 Peng, Chen, Yao, Lan, Fu, Ye, Wang, Zhao, Ji, Xia, Zhu, Zheng, Gu and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xuemei Gu, Z3V4bUB3bXUuZWR1LmNu; Kun Tang, a3VudGFuZzAwN0AxNjMuY29t

†These authors have contributed equally to this work and share last authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.